No-one is likely to forget the tragic events of 2020 and one company leading efforts to prepare for the next pandemic is Poolbeg Pharma. Optimum Strategic Communications’ Richard Staines interviewed CEO Jeremy Skillington to find the latest insights. Discussions are not about whether another pandemic will happen, but when, as a number of factors converge […]
AI analysis of unique human challenge trial data provides unparalleled insights into influenza infection Novel influenza drug targets identified faster and more cost-effectively using AI 29 June 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, announces a significant breakthrough […]
Positive results from testing SPOR-COV in several COVID-19 and influenza research models support potential as prophylactic nasal spray Toxicology studies support safety profile Manufacturing process established Manufacturing and regional licensing agreement signed with HURO Biotech JSC for Vietnam Phase 1 clinical studies completed successfully in Vietnam by HURO Retail product based on SPOR COV technology […]
Early data read out indicates a successful LPS human challenge trial Key Highlights · POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo · A clear dose-response relationship was demonstrated · Well tolerated across all doses and no serious adverse events or volunteer withdrawals were reported · Full […]
COPENHAGEN – SAN FRANCISCO – SEATTLE. Today, the Novo Nordisk Foundation, Open Philanthropy, and the Bill & Melinda Gates Foundation announced an initial commitment of up to $90 million of coordinated funding toward Pandemic Antiviral Discovery (PAD), a new initiative to catalyze discovery and early development of antiviral medicines for future pandemics. With equitable access […]
